Fusion Antibodies is a CMO that offers a range of services covering all stages of therapeutic and diagnostic antibody development from target discovery to delivery of lead optimized commercial candidates suitable for cGMP scale up.

Fusion provides contract services include...

- Antibody Humanization services

- Antibody Engineering Services

- Antibody sequencing Services

- Protein Expression & Purification Services

- Monoclonal Antibody services BLAST & Standard

- cGMP Services

Fusion Therapeutics (a division of Fusion Antibodies) is committed to developing therapeutic antibodies and recombinant proteins to disease specific markers. Fusion Therapeutics is primarily focused on the key areas of oncology and angiogenesis where immunotherapeutic intervention has a proven track record. The company’s genomic mining and proteomic discovery strategy has resulted in the development of a growing pipeline of candidate drugs. Fusion Antibodies have a number of exciting targets undergoing validation with two targets currently in preclinical trials.

Show more
Dunmurry, GB
Size (employees)
23 (est)
Fusion Antibodies was founded in 2001 and is headquartered in Dunmurry, GB
Report incorrect company information

Fusion Antibodies Office Locations

Fusion Antibodies has an office in Dunmurry
Show all (1)
Report incorrect company information

Fusion Antibodies Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$2.5 m

Latest funding size

$2.50 m

Time since last funding

11 years ago


Fusion Antibodies's latest funding round in July 2007 was reported to be $2.5 m. In total, Fusion Antibodies has raised $2.5 m
Show all financial metrics

Fusion Antibodies Financials

Fusion Antibodies's revenue was reported to be £1.91 m in FY, 2017

Revenue (FY, 2017)

1.9 m

Gross profit (FY, 2017)

961.5 k

Gross profit margin (FY, 2017), %


Net income (FY, 2017)

120 k

EBITDA (FY, 2017)

159.5 k

EBIT (FY, 2017)

126.5 k

Cash (31-Mar-2017)

285.7 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017


609.3 k455.9 k461.1 k436.9 k492.3 k435.2 k405 k723 k1.5 m1.9 m

Revenue growth, %


Cost of goods sold

802.9 k255.2 k248.6 k196.3 k298.7 k361.7 k324.2 k365.3 k618.1 k952.5 k

Gross profit

(193.6 k)200.7 k212.4 k240.6 k193.6 k73.5 k80.8 k357.7 k863.2 k961.5 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017


165.3 k436.8 k127.9 k318.5 k126.2 k45.1 k129 k139.1 k103.6 k413.9 k285.7 k

Accounts Receivable

198 k151.5 k189.4 k99.4 k263.5 k89.6 k92.1 k86.5 k205.3 k241.7 k510 k


70.3 k

Current Assets

645.3 k783.7 k508.5 k565.5 k563.8 k287.6 k248.3 k269.2 k309 k691.6 k930 k
GBPFY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2016FY, 2017

Net Income

(815.8 k)(1.1 m)(1.3 m)(960.2 k)(533.9 k)(752.2 k)(468.7 k)(113.5 k)1.2 m120 k

Cash From Operating Activities

346.6 k(37.4 k)

Cash From Financing Activities

(496 )(615 )

Net Change in Cash

310.3 k(128.3 k)
GBPY, 2017


148.2 k

Financial Leverage

1.3 x
Show all financial metrics
Report incorrect company information